Osaka City University | Date: 2017-01-25
This clamp-type ammeter has a flexible substrate of which an inner wall is configured to be able to deform into a substantially cylindrical shape. The clamp-type ammeter has a plurality of magnetic sensor elements disposed at the inner wall of the flexible substrate. The clamp-type ammeter has a tube of which one end is connected to the flexible substrate. The clamp-type ammeter has an operation unit that is connected to the other end of the tube and that can operate the deformation of the flexible substrate.
News Article | May 15, 2017
OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced today that the Japanese Ministry of Health, Labour, and Welfare (JMHLW) has approved Direct Anterior HipAlign® for use in supine position Total Hip Arthroplasty (THA) surgeries and UniAlign™ for use in Unicompartmental Knee Arthroplasty (UKA) surgeries in Japan. “I am very excited that OrthAlign technology will be available for use in Japan for supine position THAs and UKAs,” said Yukihide Minoda, MD, PhD of Osaka City University in Osaka, Japan. “I already use KneeAlign® for my TKAs and have found it to be a very important part of my surgeries. Clinically, it has been very valuable for my patients in Japan and I am very happy with the excellent outcomes. I expect the same with these new technologies.” Recent statistics have shown that the direct anterior (supine position) approach is growing in popularity amongst Japanese surgeons as it arguably leads to quicker recovery, less pain, more normal function for Japanese patients after a hip replacement, and is more minimally invasive. HipAlign provides accurate cup placement positioning and does not require any pre-operative imaging, intraoperative fluoroscopy, or additional personnel in the operating room to control components outside of the sterile field. Based on FDA cleared bench test data, HipAlign technology provides cup placement accuracy of ±3°, with at least 97% confidence. The system accounts for pelvic tilt when measuring the abduction and anteversion angles of the acetabular cup. UniAlign establishes the mechanical axis of the tibia, determining the varus/valgus angle and the posterior slope angle of the cutting block relative to the tibia, for the transverse resection. The system has been validated in simulated use testing to achieve resection accuracy of ±2.0° in the coronal plane, ±3.0° in the sagittal plane and ±2.0 mm in depth. This accuracy has been validated with at least 90% confidence. Just as KneeAlign and Posterior Approach HipAlign have been distributed in Japan through OrthAlign's partner ZimmerBiomet Japan, so too will Direct Anterior HipAlign and UniAlign. “We are very pleased with the Japanese Ministry’s approval for use of Direct Anterior HipAlign and UniAlign in Japan,” said James Young Kim, OrthAlign’s Vice President and General Manager of International. “There were approximately 20,000 supine position THAs and 8,000 UKAs completed in Japan during 2016, and these are the fastest growing procedures in joint replacement in the country. Japan is extremely important for OrthAlign's international growth strategy and we will continue providing new technologies that address the market's needs, following the successes of KneeAlign and Posterior Approach HipAlign. We are thrilled to be expanding our partnership with ZimmerBiomet Japan and hope we can continue our contribution in raising the standard of care for Japanese joint replacement surgeries.” OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit http://www.orthalign.com. “ORTHALIGN®, ORTHALIGN PLUS®, KNEEALIGN®, KNEEALIGN® 2, HIPALIGN®, and UNIALIGN™ are registered trademarks of OrthAlign, Inc.”
Osaka City University | Date: 2017-02-21
A control computation unit causes an optical modulator to change a polarization state to shift a phase of polarized light with which an object is irradiated, computes a spatial gradient of tomographic distribution of phase difference of an interference signal on the basis of phase differences of interference signals each obtained by each phase shift of the polarized light, and visually displays tomographic distribution of spatial gradient in association with tomographic distribution of stress on the display device. The control computation unit computes deformation rate vector distribution at cross-sectional positions of the object on the basis of optical interference signals, and further computes tomographic distribution of strain rate tensor. The control computation unit then computes tomographic distribution of mechanical property value from the tomographic distribution of stress and the tomographic distribution of strain rate tensor, and visually displays the tomographic distribution of mechanical property value.
Iwate University, Osaka City University, Iwate Medical University and Lotte Co. | Date: 2017-08-02
Provided is a cyclic peptide derivative which is derived from Paecilomyces tenuipes having an astrocyte proliferative activity, or a salt thereof.
Estrin Y.,Monash University |
Vinogradov A.,Osaka City University
Acta Materialia | Year: 2013
This article presents our take on the area of bulk ultrafine-grained materials produced by severe plastic deformation (SPD). Over the last decades, research activities in this area have grown enormously and have produced interesting results, which we summarise in this concise review. This paper is intended as an introduction to the field for the "uninitiated", while at the same time highlighting some polemic issues that may be of interest to those specialising in bulk nanomaterials produced by SPD. A brief overview of the available SPD technologies is given, along with a summary of unusual mechanical, physical and other properties achievable by SPD processing. The challenges this research is facing - some of them generic and some specific to the nanoSPD area - are identified and discussed. © 2012 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
SBI Pharmaceuticals Co. and Osaka City University | Date: 2016-04-27
The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX.
Shinoda S.,Osaka City University |
Shinoda S.,Japan Science and Technology Agency
Chemical Society Reviews | Year: 2013
Structural dynamism plays important roles in artificial and biological systems, because it controls structures and functions of various molecules and assemblies. In this review, molecular recognition and self-assembling behavior of dynamic armed cyclen-metal complexes are discussed at the molecular and supramolecular levels. These metal complexes provide useful platforms for molecular receptors, supramolecules, and molecular assemblies that can respond rapidly to guest molecules and environments. Since armed cyclens have many structural and geometrical variations, they form a wide variety of metal complexes having specific sensing and signaling functions. The Lewis acidity of the metal cations plays an essential role in anion binding and in hydrolytic catalysis of phosphate esters. Characteristic luminescence and magnetic properties of lanthanides also enable techniques for effective bio-imaging. They also serve as chiral building blocks for self-assembled architectures, which offer chirality integration effective for chirality sensing and signaling at the supramolecular level. © 2013 The Royal Society of Chemistry.
Osaka City University | Date: 2016-03-18
An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wherein R^(1 )is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): wherein R^(4 )is lower alkyl, R^(3 )is lower alkylene, and m is an integer of 1 to 6;
Osaka City University | Date: 2016-08-24
An electric current measurement apparatus for measuring an electric current flowing in a conducting wire in a circuit to be measured, the electric current measurement apparatus characterized by having a magnetic element to which a drive electric current terminal and a measurement voltage terminal are provided, a holder for fixing a positional relationship of the conducting wire to a magnetic body, an electric current source capable of outputting at least one frequency of alternating electric current across the drive electric current terminal, a voltage meter for measuring a voltage across the measurement voltage terminal, and a low-pass filter provided between the measurement voltage terminal and the voltage meter.
Osaka City University | Date: 2016-04-22
The purpose of the present invention is to develop and provide a nucleic acid molecule that can specifically and efficiently inhibit the activity of a target RNAi molecule and can be produced safely at a low cost. Provided is a nucleic acid molecule for inhibiting the activity of a target RNAi molecule. The nucleic acid molecule comprises a single-stranded nucleic acid moiety that contains one unmodified DNA region composed of a nucleotide sequence completely or sufficiently complementary to a nucleotide sequence of a functional strand having the activity in the target RNAi molecule and a double-stranded nucleic acid moiety to be linked to at least one of the 5-end and the 3-end of the single-stranded nucleic acid moiety.